Amgen

Pharmaceuticals
AMGN
$ 243 (0.54)%
Share price
$ 130 bn
Market Cap
$ 155 bn
Enterprise Value

Carbon footprint

1.6 Ton
GHG emissions per $ 1 mln investment
0.06x the weighted average for S&P 500
FY2020
How is this calculated?
-2.4%
YOY change in GHG emissions
Weaker than the -11% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

-14%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -5.1% weighted average for S&P 500
FY2021
How is this calculated?

Amgen aims to achieve carbon neutrality for Scope 1 + 2 by 2027


This target has not been verified as science based according to SBTi
Amgen's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Amgen's GHG emissions (market-based) (Kt of CO2e)
Amgen's Carbon intensity (Tons per 1 USDm)

Amgen's carbon footprint

Amgen reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 243 Kt (-6 /-2.4% y-o-y). Also positively, carbon intensity decreased to 9.6 t (-1.1 /-10.3% y-o-y).

Amgen's Scope 3 emissions declined to 2,627 Kt (-147 /-5.3% y-o-y). The decline accelerated compared to the CAGR of -2.7% since 4Q'18.

The company is committed to achieving carbon neutrality for Scope 1 + 2 by 2027, which translates into the estimated reduction of -35 Kt per annum over the period of FY2021 - FY2027. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Amgen aims to achive carbon neutrality across its operations (Scope 1 + 2) in 2027. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.

Company environmental metrics

Show more...